



ISSN : 2347

*Indo - American Journal of  
Life Sciences and Biotechnology*





---

## Tolerance symptoms of ketamine-A Review

Yadala Prapurna Chandra, P.Nageswari , P.Sailaja , P.Punitha

---

### Abstract

As a pharmacological phenomenon, drug tolerance occurs when the body's reaction to a medicine decreases with repeated administration, necessitating bigger dosages to have the same therapeutic effect (Editor). There are primarily two causes for tolerance to develop:

1. Pharmacokinetic: This leads to a decrease in the drug's efficacy due to its rapid metabolism.
2. Adaptive changes, including a rise or reduction in the number of receptors, as seen with morphine, occur in pharmacodynamic terms.

Ketamine is a drug that's gained popularity in recent memory as a means of managing pain, depression, and other conditions that affect individuals. The drug became known for its use in the nightclub and the rave scene, which warranted significant concern because of its intense effects. In the hands of medical professionals, ketamine treatment is a safe and effective means of managing these conditions. However, when abused, ketamine tolerance and dependence can occur, which can lead to ketamine addiction. In this blog, we'll discuss how ketamine use has become a widespread problem and how to manage ketamine tolerance. In tachyphylaxis, the drug's effect quickly decreases as a result of the depletion of mediators inside the presynaptic membrane of nerve terminals, a phenomenon comparable to tolerance. Short intervals between dosages of the medicine are what trigger this depletion. But this effect remains even after dosing increases.

---

Department of pharmacology

Ratnam Institute of Pharmacy, Pidathapolar (V), Muthukur (M), SPSR Nellore Dt.524001 A.P. India

---

[1] Consider a scenario where a contrast-enhanced computed tomography thorax was planned for a 2-month-old kid who weighed 5 kg, had a lymphovenous malformation, and had previously been subjected to nonoperative room anesthesia (NORA) with ketamine administration. Injecting glycopyrrolate (4  $\mu$ g/kg) and midazolam (0.1 mg/kg) followed by ketamine was administered to the kid in accordance with the ASA monitoring requirements for NORA. At first, the patient was given an intravenous infusion of 1 mg/kg of ketamine, but he or she stayed awake, sobbing, and moving about. The patient was not adequately sedated at a dosage of 4 mg/kg (20 mg) of ketamine, thus incremental dosing was continued until the desired effect was achieved. After 20 minutes, the baby woke up and started crying, but no side effects were seen. The metabolites of ketamine are eliminated in urine, and it functions as a receptor antagonist for N-methyl-D-aspartate. Out of the whole amount, around 80% is eliminated as glucuronic acid-hydroxylated ketamine metabolite conjugates, 16% as dehydronorketamine, 2% as norketamine, and 2% as unmetabolized potash. Research using tritium-labeled

ketamine has shown that after 5 days, the parent drug norketamine and 51% of the radioactivity that was injected were detected in the urine.

The percentage of 6-dehydronorketamine was a meager 20%. This might mean that there are still unidentified ketamine metabolites floating around, each with its own unique chemical structure and set of pharmacological effects. Its elimination time may be prolonged by 11–14 days with repeated injection of ketamine.[2] In The 5, 6-dehydronorketamine is formed when the cyclohexanone ring in ketamine is dehydrogenated; this compound has a half-life of 6-10 days. It has been shown that ketamine may activate several hepatic P450 isoforms in rat liver microsomes. These isoforms include 1A, 2B, 2E1, and 3A. When administered in a single dose, ketamine inhibits the action of cytochrome P450 (CYP) 3A4, an enzyme that breaks down erythromycin by means of N-demethylation. Nevertheless, it should be mentioned that, similar to ethanol, repeated exposure to ketamine can actually enhance the activity of CYP enzymes. The idea that tolerance might develop with long-term ketamine usage, which means greater dosages are needed to

get the desired therapeutic impact, is supported by all the processes listed above. Some of these processes include the following: the existence of unknown metabolites, the overexpression of enzymes that metabolize ketamine, the extended presence of metabolites such as 5,6-dehydronorketamine, and the frequent use of ketamine for sedation. As a result, the therapeutic benefits of ketamine can only be achieved with greater dosages.

#### **Statement of the patient's agreement**

By signing this document, the writers attest that they have collected the necessary patient permission paperwork. The form signifies that the patient or patients have granted permission for their photos and other clinical data to be published in a peer-reviewed publication. Although every attempt will be taken to ensure the patients<sup>1</sup> confidentiality, they are aware that their names and initials will not be published.

As an open access journal, the articles published here are distributed under the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License. This means that anyone can use the articles in any way they see fit, including making changes and remixes, without having to pay for the privilege. All they need to do is provide

proper attribution and license their own works under the same terms.

#### **Risks Of Ketamine Tolerance:**

While ketamine addiction is not necessarily a risk, there are still many adverse effects and uncomfortable side effects that can be experienced with this drug. When large doses of ketamine are taken, a person can have what is called a "K-Hole". This is typically thought of as one of the more unpleasant effects of ketamine. During a K-Hole, a person may be unable to move or speak and experience a slowed heart rate and slow breathing.

The risk of experiencing a K-Hole becomes stronger the more ketamine a person takes. As a person builds up a tolerance and consistently takes more, they are putting themselves at risk for a K-Hole.

#### **Referances:**

1. "General and Clinical Pharmacology" by Katzung BG, published in 2012 by McGraw-Hill Medical in New York by CZELEJ.
2. Dinis-Oliveira RJ. A toxicological approach to ketamine metabolism and metabolomics. "Forensic Science Research" published in 2017 with the DOI 2: 2510.
3. Max MB, Byas-Smith MG, Gracely RH, et al. Intravenous infusion of the NMDA antagonist,

ketamine, in chronic post-traumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. *Clin Neuropharmacol* 1995;18(4): 360–368.

4. Persson J, Axelsson G, Hallin RG, et al. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. *Pain* 1995;60(2):217–222.

5. Gammaitonie A, Gallagher RM, Welz-Bosna M. Topical ketamine gel: possible role in treating neuropathic pain. *Pain Med* 2001;1(1):97–100.

6. Haines DR, Gaines SP. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. *Pain* 1999;83(2):283–287.

7. Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. *J Pain Symptom Manage* 1999;17(5):384–386.

8. Fisher K, Hagen NA. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal

origin: a case report. *J Pain Symptom Manage* 1999; 18(1):61–66.

9. Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, cross-over, double-dose study. *J Pain Symptom Manage* 2000;20(4):246–252.

10. Lauretti GR, Gomes JMA, Reis MP, et al. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. *J Clin Anesth* 1999;11: 663–668.

11. Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. *J Pain Symptom Manage* 1999;17(4):296–300.